For the readers interested in the stock health of Brooklyn ImmunoTherapeutics Inc. (BTX). It is currently valued at $4.67. When the transactions were called off in the previous session, Stock hit the highs of $4.67, after setting-off with the price of $3.92. Company’s stock value dipped to $3.85 during the trading on the day. When the trading was stopped its value was $3.75.
Recently in News on March 25, 2021, Brooklyn ImmunoTherapeutics Completes Reverse Merger with NTN Buzztime. Shares of Brooklyn ImmunoTherapeutics to commence trading on the NYSE American on March 26, 2021 under the new ticker symbol “BTX”. You can read further details here
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Brooklyn ImmunoTherapeutics Inc. had a pretty favorable run when it comes to the market performance.
Brooklyn ImmunoTherapeutics Inc. (BTX) full year performance was 83.86%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Brooklyn ImmunoTherapeutics Inc. shares are logging -69.91% during the 52-week period from high price, and 148.40% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.88 and $15.52.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 3850738 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Brooklyn ImmunoTherapeutics Inc. (BTX) recorded performance in the market was 4.24%, having the revenues showcasing 4.24% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 6.86M, as it employees total of 22 workers.
Market experts do have their say about Brooklyn ImmunoTherapeutics Inc. (BTX)
During the last month, 0 analysts gave the Brooklyn ImmunoTherapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for BTX is recording 2.22 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.56.
Technical breakdown of Brooklyn ImmunoTherapeutics Inc. (BTX)
Bearing in mind the latest performance of Brooklyn ImmunoTherapeutics Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 4.24%. Additionally, trading for the stock in the period of the last six months notably improved by 39.82%, alongside a boost of 83.86% for the period of the last 12 months. The shares increased approximately by -1.76% in the 7-day charts and went up by -30.30% in the period of the last 30 days. Common stock shares were driven by 4.24% during last recorded quarter.